Deep Brain Provides Stimulating Market
This article was originally published in Start Up
There are signs that the field of deep brain stimulation (DBS) has gained a certain momentum of late: three start-ups raised venture rounds in 2011 and there have been two acquisitions in the space within the past year. The giants in cardiac rhythm management – Medtronic, St. Jude Medical and Boston Scientific – can leverage existing technology platforms from CRM to new diseases once served by drugs. Start-ups can help them, by validating new disease targets, and increasing procedural accuracy and efficiency.